O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
+32.08%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$4.99B
AUM Growth
+$4.99B
(+7.1%)
Cap. Flow
-$375M
Cap. Flow
% of AUM
-7.51%
Top 10 Holdings %
Top 10 Hldgs %
36.59%
Holding
136
New
14
Increased
17
Reduced
27
Closed
25
Top Buys
| 1 |
Eli Lilly
LLY
|
$105M |
| 2 |
Biogen
BIIB
|
$70.1M |
| 3 |
Elevance Health
ELV
|
$66.7M |
| 4 |
Scholar Rock
SRRK
|
$41.6M |
| 5 |
argenx
ARGX
|
$19.8M |
Top Sells
| 1 |
Humana
HUM
|
$106M |
| 2 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$85.3M |
| 3 |
Baxter International
BAX
|
$84.5M |
| 4 |
Cigna
CI
|
$66.2M |
| 5 |
AbbVie
ABBV
|
$49.2M |
Sector Composition
| 1 | Healthcare | 98.25% |
| 2 | Industrials | 1.02% |
| 3 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Neurocrine Biosciences
NBIX
$13.5B
| $68.4M | 1.37% |
519,279
+103,379
| +25% | +$13.6M |
|
27
Sarepta Therapeutics
SRPT
$1.98B
| $67.3M | 1.34% |
697,500
+168,300
| +32% | +$16.2M |
|
|
28
Elevance Health
ELV
$72.4B
| $66.7M | 1.33% |
+141,500
| New | +$66.7M |
|
|
THRD
29
DELISTED
Third Harmonic Bio
THRD
| $63.4M | 1.27% |
5,779,071
| – | – |
|
30
Natera
NTRA
$23B
| $59.8M | 1.19% |
954,481
+33,900
| +4% | +$2.12M |
|
31
Crinetics Pharmaceuticals
CRNX
$3.26B
| $59.3M | 1.18% |
1,667,360
-1,228,714
| -42% | -$43.7M |
|
32
Apellis Pharmaceuticals
APLS
$3.51B
| $55.2M | 1.1% |
922,200
-338,300
| -27% | -$20.3M |
|
|
RCM
33
DELISTED
R1 RCM Inc. Common Stock
RCM
| $50.8M | 1.01% |
4,803,200
+1,362,200
| +40% | +$14.4M |
|
34
ARS Pharmaceuticals
SPRY
$1.08B
| $50.6M | 1.01% |
9,240,887
| – | – |
|
35
Keros Therapeutics
KROS
$640M
| $50.4M | 1.01% |
1,268,734
-246,000
| -16% | -$9.78M |
|
|
36
Humana
HUM
$37.5B
| $50.3M | 1% |
109,900
-232,600
| -68% | -$106M |
|
37
Terns Pharmaceuticals
TERN
$651M
| $49.4M | 0.99% |
7,619,135
| – | – |
|
|
ALPN
38
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $48.3M | 0.97% |
2,535,245
-1,546,347
| -38% | -$29.5M |
|
39
SI-BONE Inc
SIBN
$700M
| $48.1M | 0.96% |
2,292,531
| – | – |
|
40
Prelude Therapeutics
PRLD
$69.1M
| $46.6M | 0.93% |
10,909,256
| – | – |
|
41
ALX Oncology
ALXO
$54.6M
| $46.1M | 0.92% |
3,095,000
+224,000
| +8% | +$3.34M |
|
42
Neuropace
NPCE
$310M
| $41.3M | 0.82% |
4,003,967
-8,314
| -0.2% | -$85.7K |
|
43
Iovance Biotherapeutics
IOVA
$800M
| $38.3M | 0.76% |
4,707,458
| – | – |
|
44
Syndax Pharmaceuticals
SNDX
$1.39B
| $37.8M | 0.75% |
1,749,000
+465,000
| +36% | +$10M |
|
45
Icon
ICLR
$14B
| $37.4M | 0.75% |
132,200
| – | – |
|
46
UnitedHealth
UNH
$279B
| $36.9M | 0.74% |
70,000
| – | – |
|
47
Amgen
AMGN
$153B
| $36.7M | 0.73% |
127,300
| – | – |
|
48
Apogee Therapeutics
APGE
$2.27B
| $35.7M | 0.71% |
1,277,901
-150,000
| -11% | -$4.19M |
|
49
Janux Therapeutics
JANX
$1.38B
| $35.6M | 0.71% |
3,317,927
| – | – |
|
50
Compass Therapeutics
CMPX
$466M
| $34.9M | 0.7% |
22,362,850
| – | – |
|